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Summary 
It has previously been shown that bone marrow-generated dendritic cells (DC) are potent stimu- 
lators in allogeneic mixed leukocyte reactions and are capable of activating naive CD4 § T  cells 
in  situ  in  an  antigen-specific  manner.  In  this  study  we  have  investigated  whether  bone 
marrow-generated DC are capable of inducing antigen-specific CD8 § T cell responses in vivo. 
Initial attempts to induce specific cytotoxic T lymphocyte (CTL) responses in mice injected with 
bone marrow-generated DC pulsed with ovalbumin (OVA) peptide were frustrated by the pres- 
ence of high levels of nonspecific lytic activity, which obscured,  though not completely, the 
presence of Ag-specific CTL.  Using conditions  that  effectively differentiate between antigen- 
specific and nonspecific lyric activity, we have shown that bone marrow-generated  DC pulsed 
with OVA peptide are potent inducers of OVA-specific  CTL responses in vivo, compared with 
splenocytes or RMA-S cells pulsed with OVA peptide, or compared with immunization  with 
free OVA peptide mixed with adjuvant. Antibody-mediated depletion experiments have shown 
that the cytotoxic effector cells consist primarily of CD8 § cells, and that induction of CTL in 
vivo is dependent  on CD4 §  as well as on CD8 + T  cells.  These results provide the basis for 
exploring the role of bone marrow-generated DC in major histocompatibility class I-restricted 
immune responses, and they provide the rationale for using bone marrow-generated DC in CTL- 
mediated immunotherapy  of cancer  and infectious diseases. 
T 
he dendritic cell (DC) network is a specialized system 
for presenting Ag to naive or quiescent T cells and con- 
sequently plays a central role in the induction of T  cell,  as 
well as B  cell,  immunity  in  vivo (1).  Several  studies  have 
documented the exceptional ability of DC to stimulate naive 
T cells, both in vitro and in vivo. DC are potent stimulators 
of primary MLR in  mice and in  humans  (2,  3),  and they 
are capable of sensitizing  in  situ CD4 + T  cells  to specific 
Ag in an MHC-restricted manner (4, 5). DC also stimulate 
in vitro the proliferation of allogeneic CD8 + T  cells (6,  7) 
and the generation of Ag-specific CTL from naive precursors 
(8-10). Inoculation of mice with small numbers of allogeneic 
DC (11), or with DC pulsed with peptide (12) or whole pro- 
tein (13) or transfected with DNA (14), induces strong CTL 
responses in vivo. 
Since DC are present in trace amounts,  enrichment  pro- 
tocols based on their low buoyancy, nonadherence to plastic, 
and the absence of certain cell surface markers were used to 
obtain  sufficient cells  for biological  studies.  However, the 
procedures involved were tedious and time consuming,  and 
they generated relatively low numbers of DC. Recently, Inaba 
et al. (15) have developed a protocol to generate large numbers 
of DC from myeloid progenitors present in the bone marrow 
of mice, and they have shown that the bone marrow-derived 
DC were capable of presenting mycobacterial Ags to unprimed 
CD4 § T cells in vivo (16). However, the activation of CD8 + 
cytotoxic T  cells  from  naive precursors  by bone marrow- 
generated  DC has not been yet reported. 
Our aim was to test whether bone marrow-generated DC 
are capable of inducing specific CTL against tumor cells ex- 
pressing a defned epitope. In this st,~dy we show that bone 
marrow-generated DC pulsed with an MHC class I-restricted 
peptide are potent inducers of specific  CTL against  tumor 
cells  expressing the protein containing  the CTL epitope. 
Materials  and Methods 
Mice.  5-6-wk-old female C57BL/6 mice were obtained from 
The Jackson Laboratory (Bar Harbor, ME). Mice were used at 7-10 
wk of age. 
Cell Lines and Cell Cultures.  The tumor cell lines used were 
Eb4 (C57BL/6, H-2 b, thymoma) and E.G7-OVA (Eb4 calls trans- 
fected with the chicken OVA cDNA [17]). Cells were maintained 
in DMEM supplemented with 10% heat-inactivated FCS, 2 mM 
glutamine, 100 U/ml penicillin, and 100 #g/m1 streptomycin. E.G7- 
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(GIBCO BILL, Gaithersburg, ME)). EL-4 and E.G7-OVA were free 
of mycoplasma as tested by mycoplasma  T.C. RNA detection kit 
Clen-Probe, San Diego,  CA). 
DC Generation  from Bone Marrow Cultures.  The procedure used 
in this study was described by Inaba et al. (15), with some minor 
modifications. Briefly, bone marrow was flushed from the long bones 
of the limbs and depleted of red cells with ammonium chloride. 
Bone marrow cells were depleted from lymphocytes, granulocytes, 
and Ia § cells using a cocktail of mAbs  and rabbit complement. 
The mAbs were 2.43 anti-CD8, GK1.5 anti-CD4, RA3-3A1/6.1 
anti-B220/CD45R,  B21-2 anti-Ia (TIB 210, 207,  146, and 229, 
respectively; American Type Culture Collection, Rockville, MD), 
and RB6-8C5 anti-Gr-1 (kindly provided by DNAX Corp., Palo 
Alto,  CA).  Cells  were  plated  in  six-well  culture  plates  (106 
cells/ml, 3 ml/well) in RPMI 1640 medium supplemented with 
5% heat-inactivated FCS, 50/zM 2-ME, 10 mM Hepes (pH 7.4), 
2 mM glutamine, 100 U/ml penicillin, 100/~g/ml streptomycin, 
and 3.3 ng/ml recombinant murine GM-CSF (kindly provided by 
Amgen Biologicals,  Thousand Oaks,  CA). At day 3 of culture, 
floating cells were gently removed and fresh medium was added. 
At day 7 of culture, nonadherent cells and loosely adherent prolifer- 
ating DC aggregates were collected and replated in 60-mm petri 
dishes  (10 6 cells/ml, 5 ml/dish). At 9 or 10 d of culture, nonad- 
herent cells (DC) were removed for analysis and immunizations. 
Peptides.  Peptides were synthesized by solid phase techniques 
and purified by reverse phase HPLC. The H-2Kb-restricted OVA 
peptide (amino acids [aa] 257-264, SIINFEKL; specified as ova in 
the figures) (18), and the H-2Kk-restricted influenza nucleoprotein 
peptide (aa 50-57, SDYEGRLI; specified as NP(K  k) in the figures) 
(19), were purchased from Research Genetics (Huntsville,  ALL).  The 
H-2Kb-restricted mut-1  peptide (FEQNTAQP)  (20)  was  kindly 
provided by O. Mandelboim and L. Eisenbach (Weizmann Insti- 
tute, Rehovot, Israel). 
CTL Induction in Mice.  On day 9 or day 10, DC (1-4  x  106) 
were washed once in IMDM-50/zM 2-ME and resuspended in 1 
ml of the same medium containing 100/~g of peptide. After 3 h 
of incubation at 37~  (with gentle shaking every 30 min), cells 
were washed twice in HBSS, and 10s-106 cells per mouse (in 0.5 
ml HBSS) were injected intravenously. Spleen cells were removed 
from mice 8-10 d after immunization. Splenocytes  were depleted 
of APC in two consecutive steps: (a) Splenocytes from two spleens 
were suspended in 10 ml RPMI-10% FCS and placed for 90 rain 
in a 75-cm  2 culture flask,  and nonadherent cells were collected; 
and (b) nonadherent cells were further depleted of  APC with rabbit 
complement and mAb cocktail RA3-3A1/6.1 anti-B220/CD45R, 
B21-2 anti-Ia, and Jlld anti-HSA (TIB183, American Type Cul- 
ture Collection). Alternatively, just the first step was carried out. 
Nontreated or treated splenocytes from primed mice (2  x  106/ml) 
were cultured for 5 d in vitro with irradiated (200 Gy) E.G7-OVA 
cells (2  x  10S/ml) in six-well culture plates (5 ml/well). Culture 
medium was NCTC 109 and RPMI 1640 (1:1 vol/vol) supplemented 
with 10% heat-inactivated FCS, 50/~M 2-ME, 20 mM Hepes (pH 
7.4), 2 mM glutamine, 1 mM sodium pyruvate, 0.1 mM nonessen- 
tial amino acids, 100 U/ml penicillin, and 100 #g/ml streptomycin. 
Cytotoxicity Assays.  After 5 d of restimuIation, graded doses 
of viable lymphocytes were plated in 96-well V-bottomed culture 
plates  (in  triplicates)  and  cocuhured  for  4  h  with  europium 
diethylenetriamine pentaacetate-labeled target cells (21). Europium 
diethylenetriamine pentaacetate release  was  measured by time- 
resolved fluorescence (1232 Delfia Fluorometer; Wallac, Gaithers- 
burg, MD). SEMs of triplicate cultures were <5% of the means. 
In Vivo Depletion of Immune Ceil Subsets.  mAbs against CD4 + 
T cells (GK1.5), CD8* T cells (2.43), and NKI.I* cells (PK136; 
HB191, American Type Culture Collection) were used. Mice were 
injected intravenously once with 100/zl per mouse of hybridoma 
ascites 6  d  before inoculation of DC  and then three times in- 
traperitoneally with 50-100/zl per mouse at 4-d intervals (the last 
injection was 2 d before harvesting of the spleens). Specific deple- 
tion was )>85% as determined by flow cytometry (data not shown). 
Results  and  Discussion 
Induction of OVA-specific CTL in Mice Inoculated with OVA 
Peptide-pulsed Bone Marrow-derived DC.  DC were generated 
from the bone marrow of C57BL/6 mice as described by Inaba 
et al. (15). Cell surface marker analysis, the stimulatory poten- 
tial of the DC in primary allogeneic MLR, and morpholog- 
ical analysis have confirmed that >95%  of the nonadherent 
cells present 9-10 d after initiating the bone marrow cultures 
consisted of DC  (data  not  shown).  The bone-derived DC 
were pulsed with an 8-aa-long peptide derived from chicken 
OVA (OVA peptide, aa 257-264), which encodes an H-2K  b- 
restricted epitope (18), and they were injected into mice via 
the tail vein. The presence of OVA-specific CTL in the spleen 
of immunized mice was determined after 8-10 d of in vitro 
stimulation with E.G7-OVA cells. E.G7-OVA cells were de- 
rived from EL-4 cells (H-2  b haplotype) transfected with the 
chicken OVA eDNA  (17).  E.G7-OVA  and EL-4 cells were 
used as  targets. 
In initial experiments we observed that immunization with 
bone marrow-generated  DC  induced  a  very high level of 
nonspecific lyric activity that largely obscured the presence 
of OVA-specific CTL. Nonspecific lysis was observed against 
both syngeneic and allogeneic targets, regardless of whether 
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Figure t.  Effect  of APC depletion during restimulation  on OVA-specific 
and nonspecific  lytic activities. Nonpulsed or OVA-pulsed DC (5  x  10  s 
cells per mouse) were inoculated intravenously. Splenocytes  (,4) or APC- 
depleted splenocytes  (B) were restimulated with E.G7-OVA  cells, and cyto- 
toxic activities were measured against EL-4 and E.G7-OVA target cells as 
described in Materials and Methods. The results of A and B are from the 
same experiment. 
256  CTL Induction by Bone Marrow-generated Dendritic Cells DC were or were not pulsed with peptide, and irrespective 
of the restimulator cells used or the NK/LAK sensitivity of 
the  targets  (Fig.  1 A  and  data  not  shown).  Nevertheless, 
splenocytes from mice immunized with OVA peptide-pulsed 
DC and restimulated in vitro with E.G7-OVA cells lysed E.G7- 
OVA cells above the levels of nonspecific lysis. Careful titra- 
tion of the number of injected DC revealed  that  a dose of 
0.5-1.0  x  10  s peptide-pulsed  DC  induced  high  levels  of 
specific CTL,  whereas lytic background  was reduced con- 
siderably (data not  shown). 
A  parameter  that  could have contributed  to  nonspecific 
lysis was the presence of APC in the splenocytic population 
used for restimulation in vitro. Since the bone marrow-gen- 
erated DC were cultured 6-8 d in FCS-containing medium, 
it  was  possible  that  FCS  components  such  as  BSA  were 
processed and presented by the bone marrow-generated DC, 
resulting in nonspecific proliferation and activation of T cells. 
Indeed,  Inaba et  al.  have observed that  CD4 §  T  cells  ob- 
tained from mice injected with bone marrow-generated DC 
proliferated in response to BSA (16).  We reasoned that  the 
FCS epitopes were more likely to be processed and presented 
by potent APC in the splenocytic population,  such as DC, 
macrophages, or B cells, rather than by the class II-negative 
E.G7-OVA cells used as specific restimulators.  Therefore, we 
tested whether elimination  of APC from the spleen before 
restimulation  will reduce nonspecific lytic activity.  Spleens 
from  mice  immunized  with  5  x  105  nonpulsed  or  OVA 
peptide-pulsed  DC  were harvested,  and  splenocytes were 
depleted from potential APC using complement and a cock- 
tail of mAbs against B cells and monocytes/DC. As shown 
in Fig.  1 B, this led to a significant reduction in nonspecific 
lysis with minimal reduction of specific lysis. Addition of IL-2 
(5 U/ml)  during  restimulation  of the depleted  splenocytes 
had no effect on nonspecific or specific lysis (data not shown). 
For convenience, nonadherent  splenocytes from which most 
of the DC and macrophages  and some of the B  cells were 
removed by adherence  to  plastic,  instead  of APC-depleted 
splenocytes, were used in  subsequent experiments. 
Carbone et al.  (22) have shown that in vitro stimulation 
of a primary  CTL  response could be achieved  using  OVA 
peptide-pulsed splenocytes,  although the CTL recognized and 
lysed target cells pulsed with OVA peptide but did not lyse 
cells transfected with and expressing the OVA protein.  The 
concern was raised that certain methods of immunization will 
elicit only low affinity CTL that may not be capable of recog- 
nizing  targets presenting Ag in a physiological manner.  To 
analyze the target specificity of the cytotoxic ceils elicited by 
the bone marrow-generated DC, mice were immunized with 
DC  pulsed  with  either  of two H-2Kb-restricted  peptides, 
the OVA peptide or the rout-1 peptide derived from the D122 
tumor cell line (20); stimulated in vitro with E.G7-OVA cells; 
and tested for effector functions against several targets: E.G7- 
OVA, OVA peptide-pulsed EL-4 cells,  and EL-4 cells pulsed 
with either of two unrelated peptides encoding H-2K  b- and 
H-2Kk-restricted  CTL  epitopes,  the  mut-1  peptide  and  a 
peptide  derived  from  the  influenza  virus  nucleoprotein, 
NP(K  k) (19),  respectively. As shown in Fig.  2 A,  CTL in- 
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Figure 2.  Target  specificity  of  CTL induced  by bone marrow-generated 
DC. OVA and rout-1 peptides are H-2K~  restricted, whereas NP(K  k) pep- 
tide is an H-2KLrestricted  epitope. OVA-pulsed  or mut-l-pulsed DC (1 
x  10  s cells per  mouse) were inoculated intravenously. Nonadherent 
splenocytes  were  restimulated with E.G7-OVA  cells, and cytotoxic  activi- 
ties were measured against EL-4, E.G7-OVA, and EL-4 cells pulsed with 
1/zM of OVA, mut-1, or NP(K~) peptides. The results of A and B are 
from the same experiment. 
Figure  3.  Phenotypic  analysis  of  effector  cells  responsible  for OVA-specific 
and nonspecific  lysis. OVA-pulsed  DC (1 x  10  s cells  per mouse) were in- 
oculated intravenously. Nonadherent splenocytes  were restimulated with 
E.G7-OVA cells, and viable lymphocytes  were depleted from CDS+, 
CD4 + T cells or NKI.1  +-expressing cells using complement and specific 
Ab. Lymphocytes  treated with complement alone were used as a control. 
Cytotoxic activities were measured against EL-4 (A) and E.G7-OVA (B) 
target cells. The results of A and B are from the same experiment. 
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Figure 4.  Phenotypic analysis of cells required for the induction of a  =  - 
CTL response in mice immunized with OVA-pulsed DC.  Mice were  -6/  1.8':1  " 6.5':1  "16.5:1  50:'1 
depleted from CD8 § -, CD4+-,  or NKI.1 +  -expressing cells by repeated 
injections of specific mAbs beginning 6 d before inoculation of DC (1 x 
105 cells per mouse) and up to 2 d before harvesting of splenocytes (8 d 
after inoculation of DC). Nonadherent splenocytes  were restimulated  with 
E.G7-OVA cells, and cytotoxic activities were measured against EL-4 and 
E.G7-OVA target cells. (A) CD8 + and NKI.I+  depletion; (B) CD4 + 
depletion. 
duced by DC pulsed with OVA peptide lysed EL-4 target cells 
pulsed with OVA peptide as well as cells transfected and ex- 
pressing OVA protein with the same efficiency. DC pulsed 
with the mut-1 peptide did not induce OVA-specific CTL, 
and EL-4 cells pulsed with  the two unrelated peptides  did 
not  serve as targets for OVA-specific CTL.  These observa- 
tions indicate that  the bone marrow-generated  DC pulsed 
with peptide Ag are capable of inducing high affinity CTL 
that will recognize targets presenting MHC class I-restricted 
Ag in  a physiological manner. 
Immune Cells Involved in the Response to Immunization  with 
DC.  Effector cell populations induced by immunization with 
OVA peptide-pulsed DC and restimulated in vitro by E.G7- 
OVA cells were depleted from CD4 §  CD8 §  or NKI.1 +- 
expressing cells using complement and specific Ab, and they 
were tested for effector cell function against E.G7-OVA targets. 
As shown in Fig. 3, only depletion of CD8 + cells from the 
effector cell  population  led  to  a  significant  reduction  of 
nonspecific as well as specific lytic activity, indicating that 
CD8 § CTL were primarily responsible for both specific and 
nonspecific lysis induced by bone marrow-generated DC. As 
shown  in  Fig.  4,  when  cells  were  depleted  in  vivo,  both 
CD4 §  and CD8 §  cells were found to be required for the 
induction of specific and nonspecific lytic activity, whereas 
NKl.l+-expressing  cells played no  role in either case. 
The participation of Ag-specific MHC class  II-restricted 
CD4 +  T  cells  (Th)  in  the induction  of MHC  class  1-re- 
stricted  CD8 +  CTL in  vivo is well documented  (23-26). 
E:T  ratio 
Figure 5.  CTL induction by OVA peptide-pulsed DC, splenocytes, 
KMA-S cells, and free peptide mixed with adjuvant. OVA-pulsed cells (1 
x  10  s cells per mouse) were inoculated intravenously. RMA-S cells were 
incubated at 28~  for 48 h before peptide pulsing, which was performed 
at 37~  OVA peptide (100 #g) emulsified in IFA was injected into two 
mice subcutaneously.  Nonadherent  splenocytes  were restimulated  with E.G7- 
OVA cells, and cytotoxic activities were measured against EL-4 and E.G7- 
OVA target cells. 
However, the 8-aa-long OVA peptide presented by the H-2K  b 
class I molecule is not known  to and is unlikely to encode 
an MHC class II-restricted epitope. It is therefore tempting 
to speculate that FCS components present during the gener- 
ation of DC from the bone marrow-derived precursors pro- 
vide MHC class II-restricted epitopes that stimulate CD4 + 
T cell responses and enhance the OVA-specific CTL responses 
seen in these experiments. Experiments are in progress to test 
this  hypothesis. 
Comparative Analysis of CTL Induction by Peptide-pulsed  DC, 
Splenocytes, RMA-S Cells, and Free Peptide Mixed with Adju- 
vant.  Several studies have documented the effectiveness of 
mature  DC-enriched  preparations  to  induce  CTL in  vivo 
(11-14). It was therefore of interest to test how effective the 
bone marrow-generated DC were in inducing CTL responses 
compared with other methods. It was of particular interest 
to compare DC with RMA-S cells since it was recently shown 
that RMA-S cells pulsed with peptides were also very effec- 
tive in inducing primary CTL responses in vivo and in vitro 
(20, 27, 28, and Nair, S., and E. Gilboa, manuscript in prep- 
aration). Bone marrow-generated DC, splenocytes, or RMA-S 
cells were pulsed with OVA peptide and injected into mice. 
RMA-S  cells were first incubated at 28~  for 48 h  before 
pulsing  with  peptide.  RMA-S  cells,  which  are  normally 
H-2K  b negative, reexpressed the H-2K  b Ag after incubation 
258  CTL Induction by Bone Marrow-generated Dendritic Cells with peptide (data not shown). For immunization with free 
peptide,  100 #g of OVA peptide was emulsified in IFA and 
injected subcutaneously into mice. As shown in Fig. 5, nei- 
ther splenocytes nor RMA-S cells were able to elicit a mea- 
surable CTL response, whereas administration  of free pep- 
tide in adjuvant elicited a weak CTL response. In stark contrast, 
only the bone marrow-generated DC induced a strong CTL 
response. Similar results were obtained when EL-4 cells pulsed 
with different peptides were used as targets (data not shown). 
It is also noteworthy that immunization with DC, but not 
by other methods, induced a considerable level of nonspecific 
lytic activity. 
In summary, bone marrow-generated DC, like their ma- 
ture counterparts,  are potent stimulators of CTL responses 
in vivo. Since CD8 § CTL responses play an important role 
in many infectious diseases and in cancer, it will be impor- 
tant  to  see  whether  CTL  responses  elicited  by  the  bone 
marrow-generated DC will be able to protect animals from 
infectious agents  or from  tumors. 
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